Mehmet A. Sendur

Yildirim Beyazit, Turkey

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 12 publications

Real-World Outcomes in BRAF-Mutant Non-small Cell Lung Cancer: A Multicenter Analysis From the Turkish Oncology Group.

Real-World Outcomes in BRAF-Mutant Non-small Cell Lung Cancer: A Multicenter Analysis From the Turkish Oncology Group.

Journal: Clinical lung cancer

Published: May 01, 2025

Safety of lorlatinib in ALK-positive non-small-cell lung cancer and management of central nervous system adverse events.

Safety of lorlatinib in ALK-positive non-small-cell lung cancer and management of central nervous system adverse events.

Journal: Future oncology (London, England)

Published: July 14, 2023

Neutrophil-lymphocyte ratio as a prognostic factor for survival in patients with advanced renal cell carcinoma (Turkish Oncology Group Study).

Neutrophil-lymphocyte ratio as a prognostic factor for survival in patients with advanced renal cell carcinoma (Turkish Oncology Group Study).

Journal: Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners

Published: February 15, 2020

Do tyrosine kinase inhibitors lose favor in treatment of first-line metastatic renal cell carcinoma?

Do tyrosine kinase inhibitors lose favor in treatment of first-line metastatic renal cell carcinoma?

Journal: Future oncology (London, England)

Published: March 12, 2019

Optimal regimen for treatment-naive hormone receptor-positive HER-2 negative metastatic breast cancer.

Optimal regimen for treatment-naive hormone receptor-positive HER-2 negative metastatic breast cancer.

Journal: Future oncology (London, England)

Published: November 29, 2018

The current status of adjuvant treatment for high-risk renal cell carcinoma.

The current status of adjuvant treatment for high-risk renal cell carcinoma.

Journal: Future oncology (London, England)

Published: October 07, 2017

Do all aromatase inhibitors have similar efficacy and safety?

Do all aromatase inhibitors have similar efficacy and safety?

Journal: Future oncology (London, England)

Published: August 24, 2017

Docetaxel or abiraterone in addition to androgen deprivation therapy in metastatic castration-sensitive prostate cancer.

Docetaxel or abiraterone in addition to androgen deprivation therapy in metastatic castration-sensitive prostate cancer.

Journal: Future oncology (London, England)

Published: August 23, 2017

177Lu-Dotatate for Midgut Neuroendocrine Tumors

177Lu-Dotatate for Midgut Neuroendocrine Tumors

Journal: The New England journal of medicine

Published: April 07, 2017

Syringocystadenoma papilliferum with multiple lung metastases and long survival.

Syringocystadenoma papilliferum with multiple lung metastases and long survival.

Journal: Journal of B.U.ON. : official journal of the Balkan Union of Oncology

Published: November 13, 2016

Selective internal radiation therapy in untreated patients with unresectable liver dominant metastatic colorectal cancer.

Selective internal radiation therapy in untreated patients with unresectable liver dominant metastatic colorectal cancer.

Journal: Future oncology (London, England)

Published: September 21, 2016

The effect of obesity on recurrence pattern in early breast cancer patients.

The effect of obesity on recurrence pattern in early breast cancer patients.

Journal: Journal of B.U.ON. : official journal of the Balkan Union of Oncology

Published: September 30, 2015

Showing 1-12 of 12

Last Updated: 09/26/2026